CorMedix reports Q3 net loss of $6.9M; provides DefenCath regulatory and NTAP updates

CorMedix Inc.

2022-Q3 EPS reported -$0.54 revenue$35,706

Net loss of $6.9M ($0.17 per share) improved from $8.6M loss ($0.22) in Q3 2021.
Cash and short-term investments $59.0M; sufficient to fund operations through 2023.
CMS increased NTAP reimbursement for DefenCath from $4,387.50 to $14,259.38 per visit.
CMO implemented >95% of FDA corrective actions; NDA resubmission target end of Q1 2023.
R&D expense decreased 51% to $2.3M; SG&A increased 21% to $4.6M on pre-launch activities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

CorMedix Inc. reported the third quarter of 2022 results: net income $6.9 million, EPS $0.17 per share.

Period: the third quarter of 2022
Net income: $6.9 million
EPS: $0.17 per share
Result: reported results

Exact text from the filing

For the third quarter of 2022, CorMedix recorded a net loss of $6.9 million, or $0.17 per share, compared with a net loss of $8.6 million, or $0.22 per share, in the third quarter of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

CorMedix Inc. reported the nine months ended September 30, 2022 results: net income $21.5 million, EPS $0.54 per share.

Period: the nine months ended September 30, 2022
Net income: $21.5 million
EPS: $0.54 per share
Result: reported results

Exact text from the filing

For the nine months ended September 30, 2022, CorMedix recorded a net loss of $21.5 million, or $0.54 per share, compared with a net loss of $20.4 million, or $0.54 per share, in the first nine months of 2021.

View on SEC.gov

Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-070820

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.